

University of Missouri Health

Investigation of the Effect of IL-1β, RANTES, and MMP-1 Injection into **Nucleus Pulposus of Intervertebral Disc**



Sivapiromrat AK, Stoker AM Thompson Laboratory for Regenerative Orthopaedics, University of Missouri, Columbia, MO www.thompsonlab.missouri.edu


Introduction and Purpose

- Inflammatory stimulation and degradative enzyme activity contribute to development and progression of symptomatic intervertebral disc degeneration (IVDD)
- IVDD often develops through changes in nucleus pulposus (NP) structure compromising the function of the intervertebral disc (IVD)
- The metabolic effects of injury localized and inflammation and degradative enzyme activity on the NP is poorly understood

Results

Media Biomarker Concentrations

Injury Only Injury+PBS Injury+IL-1β Injury+RANTES Injury+MMP-1



 This study was designed to determine the effects of NP stimulation with inflammatory cytokines (IL-1β and **RANTES)** and a degradative enzyme (MMP-1)

Hypotheses


 Localized stimulation of the NP in rat tail IVDs will significantly increase production of proinflammatory and degradative biomarkers Injection of inflammatory and degradative agents will significantly decrease biomechanical properties of rat tail IVDs


Methods


treatments

- MCP-1 on day 3, and significantly higher levels of MIP-1 α and MCP-1 on day 6, compared to the Injury+RANTES and Injury+MMP-1 groups.

(*) Significantly lower than Injury+IL-1β group (‡) Significantly lower than Injury only control Day 6







Anti-Inflammatory Biomarkers and Growth Factors

Creep Moduli

0.18

0.16

0.14

: 0.12


0.1

ຮັ 0.08

° 0.06 ≈


0.04

There were no significant differences between groups observed for the production of anti-inflammatory biomarkers and growth factors by the IVD in this study at any time point tested




1) With ACUC approval, rat tail IVD explants were created, and randomly assigned either control (injury only or PBS [Injury + Injection]) or treatment (IL-1β, RANTES, or MMP-1 [Injury + Injection]) groups

2) A 25G needle was used to create an injury and inject 10μ I of solution based on group.



3) Media from days 3 and 6 were collected and measured for MIP-1 α , IL-6, IL-13, IL-10, MCP-1, GRO, VEGF, IFN- γ , IL-1 β , IL-4, TIMP-1, TNF- α , RANTES, IGF-1, MMP-8, FGF- β , and



Max Force

3.0

0.7

Z 0.5

ъ́ 0.4

Day 3

Degradation-Related Biomarkers

The Injury+IL-1β group produced significantly higher levels of TIMP-1 on days 3 and 6 compared to the other injection groups.

The injury only group produced significantly higher levels of TIMP-1 on days 3 and 6 compared to the Injury+RANTES and Injury+MMP-1 groups.

(*) Significantly lower than Injury+IL-1β group (+) Significantly lower than Injury only control

Biomechanical Properties

- The creep moduli in the IL-1 β , RANTES, and MMP-1 injection groups were significantly lower than uninjured controls on day 6 of culture
- There were no significant differences in maximum force observed between groups
- (*) Significantly lower than uninjured control

Concusions



- 4) Tissue biomechanics were analyzed, and stress, strain, and creep modulus were determined.
- 5) Histological analysis was done to determine the tissue's ECM properties. Any irregularities in tissue structure were documented.
- 6) Significant differences between specific groups were assessed at each time point using an ANOVA and Tukey Post Hoc analysis with significance set at p < 0.05.

Localized IL-1ß stimulation in the NP, but not RANTES or MMP-1, increased inflammatory response by the IVD Injection of PBS in the NP after injury may decrease the pro-inflammatory responses of the IVD after injury Localized IL-1ß, RANTES, and MMP-1 stimulation in the NP decreased the biomechanical properties of the IVD

Acknowledgements: Study funded by the TLRO and The Mizzou Biojoint Innovations Funds, and IMSD Fellows Program via grant R25GM056901 from the National Institute of General Medical Science (NIGMS), a component of the National Institutes of Health (NIH)